Trileptal 300mg 50 GRAG, Oxcarbazepin
THIS IS A BRAND MEDICATION
Trileptal ® is indicated for the treatment of partial seizures (including seizure subtypes of simple, complex partial seizures that progress to secondary generalized), and generalized tonic-clonic seizures in adults and children from 1 month old .
Trileptal ® is indicated as first choice AED, either as monotherapy or adjunctive therapy.
Trileptal ® can replace other current antiepileptic treatment occurs when poorly controlled seizures (see Pharmacodynamics, Clinical Studies).
Trileptal ® is indicated for the symptomatic treatment of trigeminal neuralgia, either as monotherapy or adjunctive therapy.
CONTRAINDICATIONS: Hypersensitivity to active substance or one of the excipients.
Hypersensitivity: In the post-marketing reports have been received of hypersensitivity reaction type I (immediate), including rash, pruritus, urticaria, angioedema and anaphylaxis reports. Anafilixia cases and angioedema of the larynx, glottis, lips, eyelids have been reported in patients after the first dose or subsequent doses of Trileptal ®. If a patient develops these reactions after treatment with Trileptal ®, the drug should be discontinued and alternative therapies.
Patients should be noted that approximately 25-30% of those who have shown hypersensitivity reactions to carbamazepine may have similar reactions with Trileptal ® (see Adverse Reactions).
They can also be observed hypersensitivity reactions (including multi-organ hypersensitivity reactions) in patients without a history of hypersensitivity to carbamazepine. Such reactions can affect the skin, liver, blood, lymphatic system or other organs, either individually or jointly in the context of a systemic reaction (see Adverse Reactions). In general, Trileptal ® should be discontinued immediately if signs and symptoms suggestive of hypersensitivity reactions.
Dermatological effects, have been reported very rarely serious skin reactions in association with Trileptal ®, which have included Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell syndrome) and erythema multiforme. May be necessary to hospitalize patients with severe skin reactions, since the conditions can be very dangerous, very rarely fatal. Reactions have been associated with Trileptal ® in both children and adults. The median time to onset of reaction was 19 days. Have identified several isolated cases of recurrence of severe skin reaction when re-initiating treatment with Trileptal ®. If a patient develops a skin reaction with Trileptal ® should be considered stopping and prescribing another antiepileptic drug.
DOSAGE AND ADMINISTRATION: Oral.
ACTINIUMMR is suitable for application in monotherapy and in combination with other antiepileptic drugs.
ACTINIUMMR treatment in monotherapy and combination therapy should be instituted gradually and the dose should be tailored to individual patient needs. The dose was halved in patients with severe renal impairment.
Monotherapy: Initial dose is 300 mg a day. With concentrations of 600 to 1,200 mg daily showed good therapeutic results and most patients respond to 900 mg a day.
Combination therapy (in patients with severe epilepsy and in cases refractory to treatment): starting dose is 300 mg daily, increased gradually until optimal response. The maintenance dose ranges between 900 and 3,000 mg daily.
Children: ACTINIUMMR experience in children is limited and there is no clinical experience in children under 3 years. Regardless of whether ACTINIUMMR administered in monotherapy or combination therapy, treatment was instituted with 10 mg / kg of body weight per day and gradually increase this dosage. The maintenance dose is 30 mg / kg per day approximately.
Failure to control the crisis, individuals may increase the dose at 5 to 10 mg / kg of body weight per day.
When you can not get an accurate dose (mg / kg) in children with tablets available and treat them with ACTINIUMMR deemed necessary, the decision to give an approximate dose is taken according to the circumstances of the case.
Administration: In some patients it may be possible a regime of twice daily, but generally recommended three times daily.
The tablets should be taken during meals or after them with liquid.
Neuropathic Pain: The recommended dose for the treatment of neuropathic pain is 30 mg / kg / day or 300 mg-3, 000 mg per day, split in two to three shots.
Nombre del medicamento: Trileptal
Medicamento comparable de patente: Trileptal
Tabletas de liberación prolongada: No
Laboratorio :Novartis,S.A. de C.V.
Caja con 30 pildoras
Hecho en: Italia